Rituximab has emerged as a primary therapeutic option for idiopathic membranous nephropathy, particularly following the identification of various pathogenic autoantibodies, predominantly anti-PLA2R and anti-THSD7A [15,16]. Here, PLA2R1 is linked to membranous glomerulonephritis.